Clinical Trials Browser

Colonic Neoplasms

NCT07381777 2026-02-02

IMMUNOSTAR

Phase 2 Not yet recruiting

270 enrolled

Gastrointestinal

Locally Advanced Rectal Cancer (LARC)

NCT04165772 2026-01-23

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Phase 2 Recruiting

200 enrolled

Gastrointestinal

Rectal Neoplasms

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Active not recruiting

18 enrolled

BreastGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT07269249 2025-12-08

RW-NEDOS

Recruiting

50 enrolled

Gastrointestinal

Locally Advanced Rectal Cancer (LARC)

NCT04779151 2025-12-01

NIRADO

Phase 2 Terminated

51 enrolled

GastrointestinalGenitourinaryHead & Neck

Biliary Tract Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms

NCT04409002 2025-08-15

Niraparib + Dostarlimab + RT in Pancreatic Cancer

Phase 2 Completed

18 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04493060 2025-08-07

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

Phase 2 Completed

22 enrolled 17 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04926324 2025-06-29

A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

Phase 1/2 Terminated

3 enrolled

Gastrointestinal

Rectal Neoplasms

NCT05239546 2025-05-25

NAIO

Phase 2 Recruiting

25 enrolled

Gastrointestinal

Colonic Neoplasms

NCT06757244 2025-03-18

DOVIPA

Phase 2 Recruiting

35 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06762405 2025-02-18

PREDIR-NEOREC

Phase 3 Recruiting

68 enrolled

GastrointestinalOther solid neoplasm

Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)

NCT06365970 2025-02-03

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

Phase 2 Withdrawn

GastrointestinalOther solid neoplasm

MMR-D/MSI-H Colorectal Cancers

NCT06059495 2024-02-05

DEWI

Phase 2 Recruiting

59 enrolled

Gastrointestinal

Adenocarcinoma - GEJ

NCT04895046 2022-06-29

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

Clinical Trials

Superhero

IMMUNOSTAR

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

RW-NEDOS

NIRADO

Niraparib + Dostarlimab + RT in Pancreatic Cancer

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

NAIO

DOVIPA

PREDIR-NEOREC

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

DEWI

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma